BL-M24D1 / Biokin Pharma - LARVOL DELTA

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

BL-M24D1-101: A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Sichuan Biokin Pharmaceutical…announced that the National Medical Products Administration (NMPA) has approved its novel antibody‑drug conjugate (ADC), BL‑M24D1, to enter clinical trials as a monotherapy (flcube.com) - "The drug is indicated for patients with relapsed or refractory hematological malignancies and advanced solid tumors."

New trial • Hematological Malignancies • Solid Tumor